The Expression Heparanase in Term and Preterm Placentas
Completed
- Conditions
- Preterm Birth
- Interventions
- Other: Placental analysis
- Registration Number
- NCT03798964
- Lead Sponsor
- Hillel Yaffe Medical Center
- Brief Summary
Heparanase is an endo-β-glucuronidase that cleaves heparin-sulfate (HS) side chains of heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM).
This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) .
The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
- Singleton pregnancy
Read More
Exclusion Criteria
- High-risk patients
- Multiple pregnancy
- Significant maternal illness
- Significant fetal anomaly
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Term vaginal delivery Placental analysis Low-risk women undergoing term vaginal delivery Preterm vaginal delivery Placental analysis Women undergoing preterm vaginal delivery Elective term cesarean Placental analysis Low-risk women undergoing elective term cesarean section
- Primary Outcome Measures
Name Time Method Heparanase expression Six months Heparanase expression in the human placenta following delivery will be evaluated by western blot analysis in the three groups and will be compared to determine differences in the levels.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hille Yaffe Medical Center
🇮🇱Hadera, Israel